AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

Separately, Stifel Nicolaus cut their target price on shares of AcelRx Pharmaceuticals from $15.00 to $14.00 and set a “hold” rating for the company in a report on Tuesday, March 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. AcelRx Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.67.

AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 3.45% during mid-day trading on Tuesday, hitting $2.25. 555,447 shares of the stock traded hands. The stock’s market cap is $102.11 million. AcelRx Pharmaceuticals has a 1-year low of $1.95 and a 1-year high of $4.08. The company’s 50 day moving average price is $2.42 and its 200-day moving average price is $2.75.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.06. AcelRx Pharmaceuticals had a negative net margin of 273.65% and a negative return on equity of 478.66%. The company had revenue of $3.11 million for the quarter, compared to the consensus estimate of $2.36 million. Analysts predict that AcelRx Pharmaceuticals will post ($1.10) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/11/acelrx-pharmaceuticals-inc-acrx-lowered-to-sell-at-zacks-investment-research.html.

In related news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $2.40, for a total value of $2,100,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 28.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ACRX. ING Groep NV raised its position in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 26,000 shares during the last quarter. Acadian Asset Management LLC raised its position in AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 32,087 shares during the last quarter. Teachers Advisors LLC raised its position in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the last quarter. 30.27% of the stock is owned by institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.